Top-Up Clozapine for Risperidone LAI-Related Acute Dystonia and TR Bipolar in an Adolescent with ID- Putting the Cart before the Horse?
Affiliations
Affiliations
- Naguy, MBBCh, MSc, Child/Adolescent Psychiatrist, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St, Shuwaikh, State of Kuwait. Pridmore, MD, Professor of Psychiatry, University of Tasmania, Hobart, Australia. Singh, MBBch, MD, Mrcpsych (UK), Speciality Doctor, Learning Disabilities, Exeter, Devon NHS partnership Trust, UK, and Assistant Professor, Psychiatry, Saraswati medical college, Lucknow, India. Alamiri, MD, ABPN, ScD, Consultant Child/Adolescent Psychiatrist, Head of Al-Manara CAP Centre, KCMH, Kuwait, and, Assistant Professor, Tufts University, Medford, United States.
31 May 2022
Abstract
Objectives: Young patients with intellectual disability (ID) have both diagnostic and therapeutic challenges. These include, inter alia, diagnostic overshadowing, diagnostic slippage and heightened vulnerability to adverse drug reactions. These would portent a generally poor prognostication.
Methods: This is a case-study of an adolescent with intellectual disability long-hospitalized for co-morbid treatment-resistant bipolar mood disorder that failed to respond to ECT. Patient partially responded to LAI risperidone with repeated ADRs. Top-up with low-dose clozapine (100 mg/d) was pursued.
Results: Low-dose clozapine top-up complemented therapeutic response (mood lability and paranoia) and strikingly safeguarded effectively against risperidone-related extrapyramidal side effects.
Conclusions: Add-on clozapine remains a viable option, albeit off-label, in young patients with ID and treatment-resistant affective/schizophreniform psychoses. Clozapine has an edge over other agents in the setting of dyskinesias.
Keywords: ECT; EPS; adolescent; bipolar mood disorder; clozapine; intellectual disability; risperidone; treatment-resistance.
Similar articles
An Unexpected Circumstance: Acute Dystonic Reaction in the Setting of Clozapine Administration.
Kaplan AM, Pitts WB, Ahmed I.J Pharm Pract. 2019 Feb;32(1):103-105. doi: 10.1177/0897190017737696. Epub 2017 Nov 1.PMID: 29092658
[Antipsychotics in bipolar disorders].
Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5.PMID: 15627046 Review. French.
Treatment of generalized tardive dystonia with clozapine.
Aukst-Margetić B, Margetić B.Psychiatr Danub. 2008 Sep;20(3):329-31.PMID: 18827758
Yıldız M, Osman E.Turk Psikiyatri Derg. 2022 Summer;33(2):146-148. doi: 10.5080/u26315.PMID: 35730516 English, Turkish.
Clozapine withdrawal-emergent dystonias and dyskinesias: a case series.
Ahmed S, Chengappa KN, Naidu VR, Baker RW, Parepally H, Schooler NR.J Clin Psychiatry. 1998 Sep;59(9):472-7. doi: 10.4088/jcp.v59n0906.PMID: 9771818 Review.